Renata begins drug exports to Canada

Renata PLC, a listed drug manufacturer, has launched its first product in the Canadian pharmaceutical market.

It will sell Desogestrel/Ethinylestradiol (0.15 mg/0.03 mg) tablets, an oral contraceptive that contains two hormones, Desogestrel and Ethinylestradiol, in fixed amounts.

Manufactured at Renata's Health Canada-approved potent product facility, the medicine will be commercialised through a strategic partnership with Ambicare Pharmaceuticals Inc under the brand names Miley 21 and Miley 28, according to a disclosure posted on the Dhaka Stock Exchange (DSE) website today.

Ambicare Pharmaceuticals is a generic drugmaker with a track record of offering a broad portfolio of pharmaceutical products across multiple therapeutic areas in the Canadian market.

Renata also sells this product in Bangladesh under the brand name Desolon.

Entering the stringently regulated Canadian market through this partnership marks a milestone for Renata, as per the disclosure.

Building on its expertise in navigating other stringent regulatory markets, the company aims to replicate its past successes by expanding its product portfolio in this new territory.

However, today Renata's shares fell 0.68 percent to Tk 496 on the DSE floor.